Related Experiment Video
Updated: Apr 30, 2026

Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Identification of Novel Triazole-Pyrazole Conjugates as Potential Anticonvulsant Agents: Synthesis and Biological
Wagdy M Eldehna1, Mahmoud Abdelrahman Alkabbani2, Zainab M Elsayed3
1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, P.O. Box 33516, Kafrelsheikh 33516, Egypt.
Abstract:
Since epilepsy is still a complex neurological condition, better and more efficient treatment methods are needed. This study used PTZ- and PIL-induced seizure models to evaluate the anticonvulsant activity of some recently synthesized compounds (7a-f and 11a-c). Several candidates with significant seizure protection were found via initial screening in the PTZ model. In the pilocarpine model, compounds 7a and 11a showed the most promising efficacy by considerably delaying the start of seizures, lowering their severity, and increasing survival. According to biochemical analysis, both compounds successfully reduced oxidative stress, neuroinflammation, glial activation, and hippocampal excitotoxicity. Notably, 11a matched or surpassed valproic acid's effects, especially in lowering astrocytic activation (GFAP), while 7a performed better across all assessed parameters. The toxicological assessments validated both compounds' safety, and no evidence of neurotoxic, hepatic, renal, or cardiac damage was found. These results indicate the potential for additional preclinical development of 7a and 11a in epilepsy therapy by highlighting them as strong, safe, and versatile anticonvulsants.
Related Concept Videos
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Inhibitors of Bacterial DNA Synthesis

